Grants per year
Personal profile
Research Interests
My clinical domain is breast cancer management. My clinical research interest focuses on the development of novel therapies for the treatment of breast cancer. Clinical trials focusing on precision medicine for defining the right therapy, for the right patient at the right time is our goal. To that end, molecular interogation of breast tumors are leading to novel trial design that will hopefully translate into better outcomes for our patients. In conjuction with the developmental therapeutics program, novel agents are being incorporated into clinical trials for patients with both early and late stage disease.
Certifications and Licenses
| Internal Medicine | |
| Medical Oncology |
Training Experience
| 1986 | Residency, Michael Reese Medical Center |
| 1990 | Fellowship, University of Chicago Hospitals |
Expertise related to UN Sustainable Devlopment Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Medicine, MD, University of Illinois at Chicago
… → 1982
Research interests
- Breast Cancer
- Chemotherapy
- Clinical Research
- Drug Discovery
- Drugs (clinical pharmacology)
- Genomic Medicine/Personalized Medicine
- Medical Education
Fingerprint
Dive into the research topics where William J Gradishar is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #CT7001_001: A Modular, Multipart, Multi-arm, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-Cancer Treatments in Patients with Advanced Malignancies
Emas Pharma Limited, Carrick Therapeutics Ltd
10/15/20 → 10/15/23
Project: Research project
-
Prot #CBYL719G12301: EPIK-B2: A Two Part, Phase III, Multicenter, Randomized (1:1), Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy in Pat
Novartis Pharmaceuticals Corporation
7/1/20 → 12/31/24
Project: Research project
-
A technology-based physical activity intervention for patients with metastatic breast cancer (Fit2ThriveMB): Protocol for a randomized controlled trial
Phillips, S., Solk, P., Welch, W., Auster-Gussman, L., Lu, M., Cullather, E., Torre, E., Whitaker, M., Izenman, E., La, J., Lee, J., Spring, B. & Gradishar, W., Apr 2021, In: JMIR Research Protocols. 10, 4, e24254.Research output: Contribution to journal › Article › peer-review
Open Access -
Breast cancer, version 4.2021 featured updates to the NCCN guidelines
Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., Giordano, S. H., Goetz, M. P., Goldstein, L. J., Hurvitz, S. A., Isakoff, S. J., Jankowitz, R. C., Javid, S. H., Krishnamurthy, J., Leitch, M., Lyons, J. & 18 others, , May 2021, In: JNCCN Journal of the National Comprehensive Cancer Network. 19, 5, p. 484-494 11 p.Research output: Contribution to journal › Article › peer-review
6 Scopus citations -
Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer
Shah, A. N., Carroll, K. J., Gerratana, L., Lin, C., Davis, A. A., Zhang, Q., Jacob, S., Finkelman, B., Zhang, Y., Qiang, W., D’Amico, P., Reduzzi, C., Gradishar, W. J., Behdad, A. & Cristofanilli, M., Jun 2021, In: Breast Cancer Research and Treatment. 187, 2, p. 397-405 9 p.Research output: Contribution to journal › Article › peer-review
-
Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial
Rugo, H. S., Im, S. A., Cardoso, F., Cortés, J., Curigliano, G., Musolino, A., Pegram, M. D., Wright, G. S., Saura, C., Escrivá-De-Romaní, S., De Laurentiis, M., Levy, C., Brown-Glaberman, U., Ferrero, J. M., De Boer, M., Kim, S. B., Petráková, K., Yardley, D. A., Freedman, O., Jakobsen, E. H. & 10 others, , Apr 2021, In: JAMA Oncology. 7, 4, p. 573-584 12 p.Research output: Contribution to journal › Article › peer-review
Open Access21 Scopus citations -
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial
Hurvitz, S. A., Saura, C., Oliveira, M., Trudeau, M. E., Moy, B., Delaloge, S., Gradishar, W., Kim, S. B., Haley, B., Ryvo, L., Dai, M. S., Milovanov, V., Alarcón, J., Kalmadi, S., Cronemberger, E., Souza, C., Landeiro, L., Bose, R., Bebchuk, J., Kabbinavar, F. & 3 others, , Aug 2021, In: Oncologist. 26, 8, p. e1327-e1338Research output: Contribution to journal › Article › peer-review
Open Access